Organized by GlaxoSmithKline

Timetable: 13:45 - 15:45     Room F

The economic evaluation of new vaccines against cervical cancer relies on modeling techniques that integrate the efficacy data from randomized controlled trials, with follow-up processes of vaccinated populations over time and the extrapolation of published study results. Several cost-effectiveness models using transmission dynamic designs have been published recently but with slightly different approaches. This symposium will evaluate the conceptual and practical differences of the most recent models used and the added value of each one of them in comparison with previous approaches.

Chair: X Bosch
Co-Chair: G Garnett

13:45     Introduction
X Bosch, Head of the Epidemiology and Cancer Registry Unit, IDIBELL, Catalan Institute of Oncology, Barcelona, Spain

13:55     Measuring the direct and indirect effect of vaccines
T Van Effelterre, Mathematical Modeller, Worldwide Epidemiology Team for Vaccines, GlaxoSmithKline Biologicals, Belgium

14:10     Using hybrid (dynamic transmission and cohort) models to evaluate HPV vaccine implementation strategies
G Sanders, Associate Professor of Medicine, Duke Clinical Research Institute, Duke University, USA

14:30     Compartmental transmission dynamic models to evaluate the vaccine effect
G Garnett, Professor, Microparasite Epidemiology, Imperial College London, UK

14:50     Individual based transmission models for evaluating the joint effects of screening and vaccination
M Kretzschmar, Senior Researcher, School of Public Health, University of Bielefeld, Germany

15:10     Model choice: shedding some light on a dark art
J Edmunds, Head, Modelling and Economics Unit, Health Protection Agency, UK

15:30     Q&A